Please use this identifier to cite or link to this item: https://doi.org/10.1097/01.tp.0000166921.14670.33
DC FieldValue
dc.titleRandomized trial of alemtuzumab for prevention of graft rejection and preservation of renal function after kidney transplantation
dc.contributor.authorVathsala, A
dc.contributor.authorOna, ET
dc.contributor.authorTan, SY
dc.contributor.authorSuresh, S
dc.contributor.authorLou, HX
dc.contributor.authorCasasola, CBC
dc.contributor.authorWong, HC
dc.contributor.authorMachin, D
dc.contributor.authorChiang, GSC
dc.contributor.authorDanguilan, RA
dc.contributor.authorCalne, R
dc.date.accessioned2022-07-29T07:14:09Z
dc.date.available2022-07-29T07:14:09Z
dc.date.issued2005-09-27
dc.identifier.citationVathsala, A, Ona, ET, Tan, SY, Suresh, S, Lou, HX, Casasola, CBC, Wong, HC, Machin, D, Chiang, GSC, Danguilan, RA, Calne, R (2005-09-27). Randomized trial of alemtuzumab for prevention of graft rejection and preservation of renal function after kidney transplantation. Transplantation 80 (6) : 765-774. ScholarBank@NUS Repository. https://doi.org/10.1097/01.tp.0000166921.14670.33
dc.identifier.issn0041-1337
dc.identifier.issn1534-6080
dc.identifier.urihttps://scholarbank.nus.edu.sg/handle/10635/229456
dc.description.abstractBackground. A randomized, multicenter, controlled trial was undertaken to evaluate the safety and efficacy of Alemtuzumab, a powerful lytic agent for both T and B lymphocytes, in the prophylaxis of rejection in renal transplantation (RTx). Methods. Thirty patients were randomized to receive Alemtuzumab together with low-dose cyclosporine (CsA) monotherapy (CAMPATH, n=20) or to full doses of CsA with azathioprine and corticosteroids (Standard, n=10). CsA was administered at doses to achieve whole-blood trough CsA levels of 90 to 110 ng/mL and 180 to 225 ng/mL in CAMPATH and Standard groups, respectively. Results. Per protocol, CsA trough levels were lower in patients assigned to CAMPATH post-RTx (median trough level of 119 vs. 166 ng/mL at 6 months, CAMPATH vs. Standard; 95% confidence interval, -92 to -34). At 6 months post-RTx, serum creatinine, graft and patient survivals, incidence of biopsy proven acute rejection (25% vs. 20%, CAMPATH vs. Standard), overall treatment failure, and severe and moderate infections were comparable. Whereas all patients receiving Standard therapy required maintenance corticosteroids at 6 months, of the 17 of 20 patients with functioning grafts in CAMPATH, 15 (88%, 95% confidence interval, 53%-97%) were steroid free. Conclusion. These results suggest that Alemtuzumab is an effective induction agent that permits low-dose steroid-free immunosuppression in RTx. Copyright © 2005 by Lippincott Williams & Wilkins.
dc.publisherOvid Technologies (Wolters Kluwer Health)
dc.sourceElements
dc.subjectAdolescent
dc.subjectAdult
dc.subjectAged
dc.subjectAlemtuzumab
dc.subjectAntibodies, Monoclonal
dc.subjectAntibodies, Monoclonal, Humanized
dc.subjectAntibodies, Neoplasm
dc.subjectCyclosporine
dc.subjectFemale
dc.subjectGraft Rejection
dc.subjectHumans
dc.subjectImmunotherapy
dc.subjectKidney
dc.subjectKidney Function Tests
dc.subjectKidney Transplantation
dc.subjectMale
dc.subjectMiddle Aged
dc.subjectTime Factors
dc.typeArticle
dc.date.updated2022-07-23T14:20:22Z
dc.contributor.departmentDEPT OF SURGERY
dc.contributor.departmentMEDICINE
dc.description.doi10.1097/01.tp.0000166921.14670.33
dc.description.sourcetitleTransplantation
dc.description.volume80
dc.description.issue6
dc.description.page765-774
dc.published.statePublished
Appears in Collections:Staff Publications
Elements

Show simple item record
Files in This Item:
File Description SizeFormatAccess SettingsVersion 
Randomised Trial of Alemtuzumab - CAMPATH-1H_TRANSPLANTATION.pdf1.14 MBAdobe PDF

CLOSED

Published

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.